Our partnership policy is the cornerstone of our development. Since the very beginning, partnerships with public organisations and private companies have allowed us to develop and register treatments perfectly adapted to patients’ needs. It is through pooling the skills of all stakeholders that we will be able to deliver effective and safe treatments to patients in need.

We are actively searching for new treatments for patients, with the following characteristics :

  • having already demonstrated proof of concept (at any stage of the development cycle)
  • In diseases where the therapeutic need is high


Our research & development team plays a major role for the growth of the company thanks to in depth medical, regulatory and commercial expertise. We explore new co-development opportunities and evaluate different projects which come from academic as well as private entities.

Our strengths

We are an independent company

  • A responsive, flexible and fast decision making structure
  • Successful product launches
  • Present internationally

A team of +20 people

  • Competent, listening and reactive
  • Expertise covering the entire medicinal product life-cycle
  • More than 20 years of expertise in rare diseases and onco-haematology

A shared ambition: improve the lives of patients

  • Early market access programmes in France and internationally
  • Production adapted to limited target populations
  • Compliant and transparent for responsible communication